Biotech proved a surprisingly bright spot in 2022’s startup correction

While not totally immune to 2022’s market correction, biotech fundraising proved to be more resilient than other sectors.

Biotech proved a surprisingly bright spot in 2022’s startup correction by Rebecca Szkutak originally published on TechCrunch